First Commonwealth Financial Corp
Change company Symbol lookup
Select an option...
FCF First Commonwealth Financial Corp
PTOTF Patriot One Technologies Inc
GIM Templeton Global Income Fund
NSTC Northern Star Investment Corp III
WMLLF Wealth Minerals Ltd
NVVE Nuvve Holding Corp
ICCC ImmuCell Corp
MET MetLife Inc
FAST Fastenal Co
PFTA Portage Fintech Acquisition Corp
Go

Financials : Banks | Small Cap Value
Company profile

First Commonwealth Financial Corporation is a financial holding company for First Commonwealth Bank (the Bank). First Commonwealth Bank is a Pennsylvania bank and trust company. The Bank provides a diversified array of consumer and commercial banking services. It also provides trust and wealth management services and offers insurance products through the Bank and its other operating subsidiaries. The Bank operates approximately 118 community banking offices throughout western and central Pennsylvania, and northeastern, central and southwestern Ohio, as well as corporate banking centers in Pittsburgh, Pennsylvania, and Columbus, Canton and Cleveland, Ohio, and mortgage banking offices in Wexford, Pennsylvania, and Hudson, Westlake and Lewis Center, Ohio. The Bank also operates a network of approximately 136 automated teller machines (ATMs), at various branch offices and offsite locations.

Price
Delayed
$14.48
Day's Change
0.01 (0.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.53
Day's Low
14.39
Volume
(Light)

Today's volume of 51,899 shares is on pace to be much lighter than FCF's 10-day average volume of 338,523 shares.

51,899

KRBP FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - KRBP

1:12 pm ET October 1, 2022 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 1, 2022 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc. (NASDAQ:KRBP): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering conducted on or about July 2, 2021 (the "IPO"); and/or (ii) between June 25, 2021 and August 13, 2021, both dates inclusive (the "Class Period"), of the important October 4, 2022 lead plaintiff deadline.

Rosen Law Firm PA, Saturday, October 1, 2022, Press release picture

SO WHAT: If you purchased Kiromic BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 4, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO documents failed to disclose that the U.S. Food and Drug Administration ("FDA") had, prior to the filing of the IPO documents, imposed a clinical hold, and in fact, contained statements indicating that it had not. Given that the IPO closed on July 2, 2021, more than thirty (30) days after Kiromic BioPharma submitted the Investigational New Drug ("IND") applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

Kiromic BioPharma, however, received communications from the FDA on June 16 and 17, 2021, informing it that the FDA was placing the IND applications for its two candidate products on clinical hold. The IPO documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021. Clinical testing did not proceed in the third quarter of 2021, nor was it likely given the FDA's imposition of a clinical hold. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

lrosen@rosenlegal.com

pkim@rosenlegal.com

cases@rosenlegal.com

www.rosenlegal.com

SOURCE: The Rosen Law Firm, P.A.





View source version on accesswire.com:

https://www.accesswire.com/718349/KRBP-FINAL-DEADLINE-ROSEN-SKILLED-INVESTOR-COUNSEL-Encourages-Kiromic-BioPharma-Inc-Investors-to-Secure-Counsel-Before-Important-Tuesday-Deadline-in-Securities-Class-Action-KRBP



comtex tracking

COMTEX_415699771/2457/2022-10-01T13:12:26

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.